The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Abstract
This review highlights the evidence-based data to support current best management practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Current limitations and areas of emerging therapeutics are also emphasized. The cornerstone of palliation for patients with R/M HNSCC is a platinum-based backbone. Platinum doublets induce higher response rates than single agents but do not demonstrate a survival advantage and are associated with increased toxicity. The only regimen to demonstrate survival superiority is platinum, fluorouracil, and cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR). EGFR inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors, have achieved only modest success in R/M HNSCC, illustrating the importance of identifying predictive biomarkers and finding ways to overcome mechanisms of resistance. Although phosphoinositide 3-kinase pathway alterations are present at a high rate in HNSCC, the identification of efficacious agents in patients with activating alterations has yet to be discovered. Immunotherapy represents an attractive treatment strategy for R/M HNSCC, with promising preliminary data from studies involving immune checkpoint blockade and toll-like receptor agonists. Human papillomavirus has a prognostic role in R/M disease; therefore, stratification of patients by human papillomavirus status in clinical trials is indicated. Although under-represented in clinical trials, elderly patients experience similar survival outcomes compared with younger patients, albeit with increased toxicity. Despite therapeutic advances, prognosis nonetheless remains poor for patients with R/M HNSCC. Enrollment of patients onto clinical trials to investigate novel therapeutics and identify predictive biomarkers is necessary to further refine and improve outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Ang, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R. L., Hammond, E. H., Fu, K. K., & Milas, L. (2002) · PubMed · Cited by 1,198
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Grandis, J. R., & Tweardy, D. J. (1993) · PubMed · Cited by 851
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Forastiere, A. A., Metch, B., Schuller, D. E., Ensley, J. F., Hutchins, L. F., Triozzi, P., Kish, J. A., McClure, S., VonFeldt, E., & Williamson, S. K. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1245 · Cited by 752
Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.4.489 · Cited by 739
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
Self-citationBadoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2606 · Cited by 633
Jacobs, C., Lyman, G., Velez-García, E., Sridhar, K. S., Knight, W., Hochster, H., Goodnough, L. T., Mortimer, J. E., Einhorn, L. H., & Schacter, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.257 · Cited by 628
Goodwin, W. J. (2000) · The Laryngoscope · doi:10.1097/00005537-200003001-00001 · Cited by 596
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
Fakhry, C., Zhang, Q., Nguyen-Tan, P. F., Rosenthal, D., El-Naggar, A., Garden, A. S., Soulieres, D., Trotti, A., Avizonis, V., Ridge, J. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1937 · Cited by 550
Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H. A., DeConti, R. C., Ensley, J., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.057 · Cited by 496
Vermorken, J. B., Stöhlmacher-Williams, J., Davidenko, I., Licitra, L., Winquist, E., Villanueva, C., Foa, P., Rottey, S., Skladowski, K., Tahara, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70181-5 · Cited by 440
Janot, F., de Raucourt, D., Benhamou, E., Ferron, C., Dolivet, G., Bensadoun, R.-J., Hamoir, M., Géry, B., Julieron, M., Castaing, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0102 · Cited by 405
Stewart, J. S. W., Cohen, E. E. W., Licitra, L., Van Herpen, C. M. L., Khorprasert, C., Soulieres, D., Vodvarka, P., Rischin, D., Garin, A. M., Hirsch, F. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0530 · Cited by 382
Self-citationColevas, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3348 · Cited by 257
Machiels, J.-P., Subramanian, S., Ruzsa, A., Repassy, G., Lifirenko, I., Flygare, A., Sørensen, P., Nielsen, T., Lisby, S., & Clement, P. M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70034-1 · Cited by 245
Licitra, L., Mesia, R., Rivera, F., Remenár, É., Hitt, R., Erfán, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq588 · Cited by 229
Hitt, R., Irigoyen, A., Cortes-Funes, H., Grau, J. J., García-Sáenz, J. A., & Cruz-Hernandez, J. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr367 · Cited by 223
Argiris, A., Ghebremichael, M., Gilbert, J., Lee, J.-W., Sachidanandam, K., Kolesar, J. M., Burtness, B., & Forastiere, A. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.4272 · Cited by 212
Seiwert, T. Y., Fayette, J., Cupissol, D., del Campo, J. M., Clement, P. M., Hitt, R., Degardin, M., Zhang, W., Blackman, A., Ehrnrooth, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu216 · Cited by 181
Self-citationLicitra, L., Störkel, S., Kerr, K. M., Van Cutsem, E., Pirker, R., Hirsch, F. R., Vermorken, J. B., von Heydebreck, A., Esser, R., Celik, I., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.018 · Cited by 167
CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck.
Wittes, R. E., Cvitkovic, E., Shah, J., Gerold, F. P., & Strong, E. W. (1977) · PubMed · Cited by 156
Argiris, A. E., Li, Y., Murphy, B. A., Langer, C. J., & Forastiere, A. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.039 · Cited by 152
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
de Souza, J. A., Davis, D. W., Zhang, Y., Khattri, A., Seiwert, T. Y., Aktolga, S., Wong, S. J., Kozloff, M. F., Nattam, S. R., Lingen, M. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2825 · Cited by 119
Self-citationRazak, A. R. A., Soulières, D., Laurie, S. A., Hotte, S. J., Singh, S., Winquist, E., Chia, S., Tourneau, C. L., Nguyen‐Tan, P. F., Chen, E. X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds503 · Cited by 113
Argiris, A. E., Li, S., Ghebremichael, M. S., Egloff, A. M., Wang, L., Forastiere, A. A., Burtness, B. A., & Mehra, R. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu167 · Cited by 106
Browman, G. P., & Cronin, L. (1994) · PubMed · Cited by 101
Jimeno, A., Shirai, K., Choi, M., Laskin, J. J., Kochenderfer, M. D., Spira, A. I., Cline-Burkhardt, V. J. M., Winquist, E., Hausman, D. F., Walker, L. N., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu574 · Cited by 99
Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature
Rabinowits, G., & Haddad, R. I. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.016 · Cited by 89
Shin, D. M., Khuri, F. R., Glisson, B. S., Ginsberg, L. E., Papadimitrakopoulou, V., Clayman, G. L., Lee, J. J., Ang, K. K., Lippman, S. M., & Hong, W. K. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1316::aid-cncr1134>3.0.co;2-0 · Cited by 78
Jimeno, A., Bauman, J. E., Weissman, C., Adkins, D. R., Schnadig, I. D., Beauregard, P., Bowles, D. W., Spira, A. I., Levy, B. P., Seetharamu, N., et al. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.12.013 · Cited by 78
Kim, H. S., Kwon, H. J., Jung, I., Yun, M. R., Ahn, M., Kang, B. W., Sun, J., Kim, S. B., Yoon, D.-H., Park, K. U., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1756 · Cited by 74
Grünwald, V., Keilholz, U., Boehm, A., Guntinas‐Lichius, O., Hennemann, B., Schmoll, H., Ivanyi, P., Abbas, M., Lehmann, U., Koch, A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu571 · Cited by 64
Saba, N. F., Hurwitz, S. J., Magliocca, K. R., Kim, S., Owonikoko, T. K., Harvey, D., Ramalingam, S. S., Chen, Z., Rogerio, J., Sheldon, J. M., et al. (2014) · Cancer · doi:10.1002/cncr.28965 · Cited by 54
Gonzalez-Angulo, A. M., Juric, D., Argilés, G., Schellens, J. H. M., Burris, H. A., Berlin, J. D., Middleton, M. R., Schüler, M., van Geel, R. M. J. M., Helgason, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2531 · Cited by 52
Urba, S. G., van Herpen, C. M. L., Sahoo, T. P., Shin, D. M., Licitra, L. F., Mezei, K., Reuter, C. W., Hitt, R., Russo, F. P., Chang, S., et al. (2012) · Cancer · doi:10.1002/cncr.27449 · Cited by 50
Fury, M. G., Sherman, E. J., Ho, A. L., Katabi, N., Sima, C. S., Kelly, K. W., Nwankwo, O., Haque, S. S., & Pfister, D. G. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1894-y · Cited by 37
Mountzios, G. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i1.7 · Cited by 37
Kuo, W.-L., Sharifi, M. N., Lingen, M. W., Ahmed, O. G., Liu, J., Nagilla, M., Macleod, K. F., & Cohen, E. E. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090171 · Cited by 34
Self-citationFury, M. G., Ou, S. I., Balmanoukian, A. S., Hansen, A. R., Massarelli, E., Blake-Haskins, A., Li, X., Robbins, P. B., Vasselli, J., & Segal, N. H. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu340.3 · Cited by 32
Chow, L. Q. M., Burtness, B. A., Weiss, J. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.32 · Cited by 31
Programmed death-ligand 1 (PD-L1) expression in various tumor types
Grosso, J. F., Inzunza, H. D., Wu, Q., Simon, J. S., Singh, P., Zhang, X., Phillips, T., Simmons, P., & Cogswell, J. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-s1-p53 · Cited by 29
Wirth, L. J., Dakhil, S. R., Kornek, G. V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.6029 · Cited by 20
Cited by
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Steuer, C. E., El‐Deiry, M., Parks, J. R., Higgins, K. A., & Saba, N. F. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21386 · Cited by 672
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance
Wang, C., Li, Y., Jia, L., Kim, J. K., Li, J., Deng, P., Zhang, W., Krebsbach, P. H., & Wang, C.-Y. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.04.011 · Cited by 304
Sacco, A. G., Chen, R., Worden, F. P., Wong, D. J. L., Adkins, D., Swiecicki, P., Chai-Ho, W., Oppelt, P., Ghosh, D., Bykowski, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00136-4 · Cited by 271
Self-citationA Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
Samaraweera, L., Adomako, A., Rodriguez-Gabin, A., & McDaid, H. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-01964-1 · Cited by 183
Metadata
- Authors
- Sacco, A. G., & Cohen, E. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-10-10
- Volume
- 33
- Issue
- 29
- Pages
- 3305-3313
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2124462445
- Cited by
- 343
- References
- 50
- FWCI
- 26.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.